Rani Therapeutics Hldgs 株価情報 (NASDAQ: RANI)

Rani Therapeutics Hldgs (NASDAQ:RANI) 株価情報

RANI THERAPEUTICS HOLDINGS-A

Rani Therapeutics Hldgs

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Holdings Inc

Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.66) by 22.73 percent. This is a 30.14 percent increase over losses of $(0.73) per share from the same period last year.

Earnings

Earnings Beats

News

ACRV

Acrivon Therapeutics Q1 EPS $(0.51) Beats $(0.66) Estimate

Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) reported quarterly losses of $(0.05) per share. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $41.56 million in sales this quarter. This is a 8.55 percent decrease over sales of $45.45 million the same period last year.

Harte-Hanks Q1 Adj. EPS $(0.05) Down From $(0.02) YoY, Sales $41.56M Down From $45.45M YoY

Insider Trades

Co-Founder, CEO And CFO Aiden Lee Ping Wei Reports 48.9% Stake In Graphjet Technology

Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported $29.51 million in sales this quarter. This is a 17.00 percent decrease over sales of $35.55 million the same period last year.

SYPR

Sypris Solutions Q1 EPS $(0.04) Up From $(0.10) YoY, Sales $29.51M Down From $35.55M YoY

Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.61) by 8.2 percent. This is a 26.32 percent increase over losses of $(0.76) per share from the same period last year.

ANRO

Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate

CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) reported financial results for the first quarter after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45419679/coreweave-reports-strong-first-quarter-2025-results">of the report</a>.
Q1 Earnings: CoreWeave reported first-quarter revenue of $981.63 million, beating analyst <a href="http://benzinga.com/quote/crwv/earnings">estimates</a> of $859.77 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter adjusted loss of $1.49 per share.
Total revenue was up 420% on a year-over-year basis. The company said it ended the quarter with a revenue backlog of $25.9 billion. CoreWeave noted that a strategic deal with OpenAI during the quarter added $11.2 billion in revenue backlog. 
The company reported $1.01 billion in operating expenses during the period, up 487% year-over-year, and ended the quarter with $1.28 billion in cash and cash equivalents. 
&#8220;We&#8217;ve delivered an outstanding start to 2025 on multiple fronts. Our strong&nbsp;first quarter&nbsp;financial performance caps a string of milestones including our IPO, our major strategic deal with OpenAI as well as other customer wins, our acquisition of Weights &amp; Biases and many technical achievements,&#8221; said Michael Intrator, co-founder and CEO of CoreWeave.
&#8220;Demand for our platform is robust and accelerating as AI leaders seek the highly performant AI cloud infrastructure required for the most advanced applications. We are scaling as fast as possible to capture that demand. The future runs on CoreWeave.&#8221;
CoreWeave executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET. The company noted that it will provide forward guidance on the call.
CoreWeave has operated data centers across the U.S. and&nbsp;Europe since 2017. The company provides access to Nvidia GPUs to large technology and AI-focused companies.&nbsp;CoreWeave made its public debut on the Nasdaq at $40 per share in March.
CRWV Price Action: <a href="http://benzinga.com/quote/crwv">CoreWeave shares</a> were trading at all-time highs heading into Wednesday&#8217;s report, its first as a public company. The stock was up 7.92% at $68.97, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a></li>
</ul>
Photo: Shutterstock.

Guidance

Movers

Tech

CRWV

Nvidia-Backed CoreWeave Reports Q1 Earnings: Revenue Jumps 420%, Backlog Grows To $25.9 Billion Following OpenAI Deal, Shares Hit All-Time Highs

WIIM

CoreWeave shares are trading higher following Q1 financial results.

Inhibrx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBX#NASDAQ">INBX</a>) reported quarterly losses of $(2.80) per share which beat the analyst consensus estimate of $(2.84) by 1.41 percent. This is a 51.47 percent increase over losses of $(5.77) per share from the same period last year.

INBX

Inhibrx Q1 EPS $(2.80) Beats $(2.84) Estimate

Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.38) by 47.37 percent. This is a 71.01 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $491.00 thousand which missed the analyst consensus estimate of $1.38 million by 64.42 percent. This is a 49.17 percent decrease over sales of $966.00 thousand the same period last year.

Earnings Misses

ARMP

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for FY2026 Adj EPS of $2.75-$3.25 vs $3.41 analyst estimate. sees sales of $12.180 billion-$12.440 billion vs $12.41 billion analyst estimate.

DXC Technology Sees FY2026 Adj EPS $2.75-$3.25 vs $3.41 Est; Sees Sales $12.180B-$12.440B vs $12.41B Est

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for Q1 Adj EPS of $0.55-$0.65 vs $0.77 analyst estimate. sees sales of $3.040 billion-$3.090 billion vs $3.12 billion analyst estimate.

DXC Technology Sees Q1 Adj EPS $0.55-$0.65 vs $0.77 Est; Sees Sales $3.040B-$3.090B vs $3.12B Est

SPACE

General

RKLB

NASA Selects Rocket Lab To Launch Aspera Mission To Study Galaxy Evolution

Okeanis Eco Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECO#NYSE">ECO</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.24 by 50 percent. This is a 70.73 percent decrease over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $80.15 million which beat the analyst consensus estimate of $74.56 million by 7.49 percent. This is a 27.95 percent decrease over sales of $111.23 million the same period last year.

Okeanis Eco Tankers Q1 Adj. EPS $0.36 Beats $0.24 Estimate, Sales $80.15M Beat $74.56M Estimate

CSCO

Cisco Says EPS Guidance Includes Estimated Impact Of Tariffs Based On Current Trade Policy; AI Infrastructure Orders Surpassing Our $1B Target One Quarter Early

GEE Group Q2 Adj. EPS $(0.30), Sales $24.50M Down From $28.05M YoY

Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share from the same period last year.

Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate

BNGO

Bionano Genomics shares are trading higher following better-than-expected Q1 reported financial results.

Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.30) by 73.33 percent. This is a 89.87 percent increase over losses of $(0.79) per share from the same period last year.

ELDN

Eledon Pharma Q1 EPS $(0.08) Beats $(0.30) Estimate

Gold miners&#8217; stocks, 2025&#8217;s standout performers, faced a sharp reversal this week as investor appetite for safe havens cooled following the U.S.-China trade truce, raising fresh doubts about the sustainability of<a href="https://www.benzinga.com/topic/gold-miners"> the sector&#8217;s explosive rally.</a>
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)—a widely tracked proxy for gold mining stocks—plunged 9.6% over three sessions, marking its worst three-day performance since April 2022. 
The move was amplified by a 4.4% drop in gold prices, which now sit 9.2% below the all-time high of $3,500 per ounce reached on April 22.
Losses were broad-based within the GDX components. Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), its largest holding, dropped 10% in just three days. Similar losses were recorded in Barrick Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) and Agnico Eagle Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>).
The abrupt reversal comes as risk appetite surges globally, diminishing gold's appeal. The May 12 announcement of a 90-day U.S.-China tariff rollback helped lift equities and risk assets, reducing investor hedges in gold.
<h3 class="wp-block-heading">Technical Setups Signal Caution For Gold</h3>
Technical analysts are growing cautious. Bank of America technical analyst, Paul Ciana said the daily gold chart is showing signs of a potential double top pattern. 
He indicated that a close below $3,200 per ounce would increase the risk of a correction to the $2,900–$3,000 range during the second quarter.
From a fundamental view, David Morrison, senior market analyst at Trade Nation, observed that gold is consolidating around the lower end of its recent range. 
He flagged $3,200 as the first key support level. "It looks as if the path of least resistance may be down for gold, although much now depends on how staunchly the bulls can defend the $3,200 level," he said.
Nikos Tzabouras, senior market analyst at Tradu.com, said the trade truce buoyed market sentiment and reduced near-term demand for havens like gold. 
"Gold remains under pressure, with scope for further declines as risk appetite holds firm," he said, while cautioning that geopolitical uncertainty and central bank buying still support the longer-term case.
<h3 class="wp-block-heading">Seasonality Enters Choppy Phase</h3>
Seasonal trends may also be at play. Historically, gold posts strong gains in the first four months of the year, followed by a choppy stretch between mid-May and mid-July. In that two-month window, bullion has delivered positive returns just 42% of the time over the past decade.
This seasonal lull could compound downside pressure, especially if key support levels fail to hold.
Conclusion: Time to Take Some Chips Off the Table?
While gold miners have delivered strong year-to-date returns – with the GDX ETF up 30% through mid May. 
Yet, the combination of technical weakness, a seasonally soft window, and shifting macro tailwinds suggests a more cautious stance may be warranted in the short term. 
For investors sitting on large gains, this could be an opportune moment to lock in profits—or at least tighten risk controls—while waiting for clearer signals.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45410216/cruises-set-sail-ahead-of-summer-boom-these-3-sp-500-stocks-show-strongest-late-may-seasonality">Cruises Set Sail Ahead Of Summer Boom: These 3 S&amp;P 500 Stocks Show Strongest Late-May Seasonality</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Macro Economic Events

Sector ETFs

Econ #s

Economics

Analyst Ratings

ETFs

Market Vectors ETF Trust Market Vectors Gold Miners

GOLD

Gold Miners Slammed By US-China Trade Truce: Is It Time To Take Profit?

BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.39) by 51.28 percent. This is a 56.3 percent increase over losses of $(1.35) per share from the same period last year.

BCDA

BioCardia Q1 EPS $(0.59) Misses $(0.39) Estimate

Press Releases

"Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology" more stocks inside….

Health Care

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Rani Therapeutics to Participate in Upcoming Investor Conferences

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

BNZI

BREA

DRUG

ILLR

NIVF

NIXX

PRSO

RANI

STAF

TVGN

VMAR

VSME

XPON

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

Talphera

TherapeuticsMD

VYNE Therapeutics

HC Wainwright & Co.

Canaccord Genuity

Oppenheimer

Maxim Group

Rani Therapeutics Holdings shares are trading higher. The company reported Q1 financial results.

Comments

Rani Therapeutics Hldgs

ニュース

パートナーシップ

ベンジンガ・グローバル